230 related articles for article (PubMed ID: 15771960)
1. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1.
Nasimuzzaman M; Kuroda M; Dohno S; Yamamoto T; Iwatsuki K; Matsuzaki S; Mohammad R; Kumita W; Mizuguchi H; Hayakawa T; Nakamura H; Taguchi T; Wakiguchi H; Imai S
Mol Ther; 2005 Apr; 11(4):578-90. PubMed ID: 15771960
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic inhibition of Epstein-Barr virus-associated tumor cell growth by dominant-negative EBNA1].
Imai S; Kuroda M; Yamashita R; Ishiura Y
Uirusu; 2005 Dec; 55(2):239-49. PubMed ID: 16557009
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.
Hong M; Murai Y; Kutsuna T; Takahashi H; Nomoto K; Cheng CM; Ishizawa S; Zhao QL; Ogawa R; Harmon BV; Tsuneyama K; Takano Y
J Cancer Res Clin Oncol; 2006 Jan; 132(1):1-8. PubMed ID: 16180023
[TBL] [Abstract][Full Text] [Related]
4. Structural and Functional Basis for an EBNA1 Hexameric Ring in Epstein-Barr Virus Episome Maintenance.
Deakyne JS; Malecka KA; Messick TE; Lieberman PM
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701406
[TBL] [Abstract][Full Text] [Related]
5. [Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy].
Noguchi K
Yakugaku Zasshi; 2019; 139(1):63-67. PubMed ID: 30606931
[TBL] [Abstract][Full Text] [Related]
6. HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr Virus.
Dheekollu J; Wiedmer A; Sentana-Lledo D; Cassel J; Messick T; Lieberman PM
J Virol; 2016 Jun; 90(11):5353-5367. PubMed ID: 27009953
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells.
Dorigo O; Gil JS; Gallaher SD; Tan BT; Castro MG; Lowenstein PR; Calos MP; Berk AJ
J Virol; 2004 Jun; 78(12):6556-66. PubMed ID: 15163748
[TBL] [Abstract][Full Text] [Related]
8. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
9. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription.
Liu CD; Lee HL; Peng CW
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing.
Jones RJ; Smith LJ; Dawson CW; Haigh T; Blake NW; Young LS
Virology; 2003 Sep; 313(2):663-76. PubMed ID: 12954232
[TBL] [Abstract][Full Text] [Related]
11. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
[TBL] [Abstract][Full Text] [Related]
12. Targeted disruption of EBNA1 in EBV-infected cells attenuated cell growth.
Noh KW; Park J; Kang MS
BMB Rep; 2016 Apr; 49(4):226-31. PubMed ID: 26879316
[TBL] [Abstract][Full Text] [Related]
13. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells.
Yin Q; Flemington EK
Virology; 2006 Mar; 346(2):385-93. PubMed ID: 16343579
[TBL] [Abstract][Full Text] [Related]
14. DNA ligand designed to antagonize EBNA1 represses Epstein-Barr virus-induced immortalization.
Yasuda A; Noguchi K; Minoshima M; Kashiwazaki G; Kanda T; Katayama K; Mitsuhashi J; Bando T; Sugiyama H; Sugimoto Y
Cancer Sci; 2011 Dec; 102(12):2221-30. PubMed ID: 21910783
[TBL] [Abstract][Full Text] [Related]
15. Robust in vivo transduction of a genetically stable Epstein-Barr virus episome to hepatocytes in mice by a hybrid viral vector.
Gallaher SD; Gil JS; Dorigo O; Berk AJ
J Virol; 2009 Apr; 83(7):3249-57. PubMed ID: 19158239
[TBL] [Abstract][Full Text] [Related]
16. GAP31 from an ancient medicinal plant exhibits anti-viral activity through targeting to Epstein-Barr virus nuclear antigen 1.
Shen CL; Huang WH; Hsu HJ; Yang JH; Peng CW
Antiviral Res; 2019 Apr; 164():123-130. PubMed ID: 30817940
[TBL] [Abstract][Full Text] [Related]
17. Galectin-9 Facilitates Epstein-Barr Virus Latent Infection and Lymphomagenesis in Human B Cells.
Xu JX; Zhang R; Huang DJ; Tang Y; Ping LQ; Huang BJ; Huang HQ; Busson P; Li J
Microbiol Spectr; 2023 Feb; 11(1):e0493222. PubMed ID: 36622166
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of the viral episome is essential for the cell survival of an Epstein-Barr virus positive gastric carcinoma cell line.
Oh ST; Kim M; Lee SK
Arch Pharm Res; 2009 May; 32(5):729-36. PubMed ID: 19471888
[TBL] [Abstract][Full Text] [Related]
20. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
